Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

Author： Pectasides Dimitris   Psyrri Amanda   Pectasides Melina   Economopoulos Theofanis  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.8, 2006-06, pp. : 975-987

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

By Naumann R. Wendel  

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1397-1412

Adis International

Access to resources Recommend Favorite

Treatment of platinum-resistant ovarian cancer

By Trimble Edward L   Wright John   Christian Michaele C  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 8, 2001-08 ,pp. : 1299-1306

Informa Healthcare

Access to resources Recommend Favorite

Investigational agents against platinum-resistant ovarian cancer

By Lorusso Domenica   Ferrandina Gabriella   Fanfani Francesco   Gagliardi Maria Lucia   Scambia Giovanni  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 325-336

Informa Healthcare

Access to resources Recommend Favorite

Combination gemcitabine + cisplatin therapy for recurrent ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Belotecan shows promise in both platinum-resistant and -sensitive ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1648, 2008-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite